Mitsubishi Tanabe Pharma Europe Ltd is the European Headquarters of one of Japan’s largest pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation.
Mitsubishi Tanabe Pharma Corporation is a research-based pharmaceutical company, created through the merger of Tanabe Seiyaku Co., and Mitsubishi Pharma Corporation on 1st October 2007, based in Osaka, Japan.
Mitsubishi Tanabe Pharma Corporation is committed to becoming a global research-driven pharmaceutical company, which continuously brings new medicines to market that meet global needs. As part of the company’s worldwide expansion, organisations have been established in the United Kingdom (Mitsubishi Tanabe Pharma Europe Ltd) and Germany (Mitsubishi Tanabe Pharma GmbH).
For more information, please contact us.
It is our policy to assure the quality, efficacy and safety of our products and the integrity of data throughout the product lifecycle, from research and development through manufacturing and post-marketing activities, in order to provide each customer, internal or external, with accurate information, services, products and communications that are suitable for their intended purpose.
We aim to create and foster a professional working environment in which suitably experienced, qualified and trained personnel work in a manner that complies with or exceeds the requirements of relevant standards, guidelines and regulations. Success includes execution of continuous improvements and defect prevention.
We are committed to working in accordance with the content of the global policies for Quality Assurance and “Basic Principles for Clinical Trials”, of our parent company, Mitsubishi Tanabe Pharma Corporation, and to work with service providers that perform their work in accordance with the relevant good practice (GxP) quality guidelines and regulations.
We are committed to improving the quality of the processes, products and services that we provide to our customers.
Code of Ethics
We are firmly committed to the highest ethical standards in our dealings with all those with whom we are involved. We will follow good business practice and ensure the accuracy of our records and business information. In our business practice, we will comply with the laws of all jurisdictions in which we operate and with applicable international and national industry codes of practice.
Anti-Bribery & Corruption
The Company does not tolerate and strictly opposes corruption and bribery in our businesses. Mitsubishi Tanabe Pharma Group does not seek business by trying to corrupt the judgement of our customers and we do not tolerate any corruption or bribery of private or public persons.
It is our policy to conduct all our business in an honest and ethical manner. We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally, fairly and with integrity in all our business dealings and relationships wherever we operate and implementing and enforcing effective systems to counter bribery and corruption.
Our Tax Strategy
We follow our Global Tax Strategy published by our ultimate parent company Mitsubishi Chemical Holdings Corporation. This tax strategy applies to UK taxation and has been published to satisfy our duty under paragraph 16(2) Schedule 19 Finance Act 2016 for the financial year ended 31 March 2022.